Compare OCSL & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCSL | SDGR |
|---|---|---|
| Founded | 2007 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 856.7M |
| IPO Year | 2007 | 2020 |
| Metric | OCSL | SDGR |
|---|---|---|
| Price | $11.27 | $12.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 8 |
| Target Price | $13.10 | ★ $21.13 |
| AVG Volume (30 Days) | 884.3K | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-28-2026 |
| Dividend Yield | ★ 14.32% | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | ★ $255,869,000.00 |
| Revenue This Year | N/A | $6.11 |
| Revenue Next Year | $0.30 | $7.69 |
| P/E Ratio | $186.25 | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $10.63 | $11.11 |
| 52 Week High | $15.85 | $27.63 |
| Indicator | OCSL | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 43.17 | 41.77 |
| Support Level | $11.09 | $11.11 |
| Resistance Level | $13.89 | $13.36 |
| Average True Range (ATR) | 0.27 | 0.65 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 61.36 | 37.37 |
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.